Scroll to explore
We make innovative vaccines and specialty medicines to prevent and treat disease. Our R&D focuses on the science of the immune system, human genetics and advanced technologies.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Behind the science
Discover how we're getting ahead
Unlocking the power of the immune system to get ahead of hepatitis B
Tackling tomorrow’s health challenges today
How vaccine science can help tackle antimicrobial resistance
The 40 year fight against HIV
How the next generation of immuno-oncology could help us get ahead of cancer
1.4 million reasons to get ahead of gynaecologic cancers
Digital twin: using advanced technology to accelerate vaccine development
What if remission were the target of lupus care?
Synthetic Lethality: accelerating precision cancer treatments
Tech for T-cells single cell RNA seq measures shifts in immune cells to pinpoint causes of disease
Life at GSK
How we help people thrive
Diversity, equity and inclusion
In the spotlight
GSK on social
#News for #Investors and #Media. Today we announced the completion of the acquisition of @Affinivax. This news follows our recent acquisition of @sierraoncology as we continue to focus on developing a strong portfolio of innovative vaccines and specialty medicines.
Alison, Head of Strategy, Planning and Campaigns, helps create impactful and timely campaigns to inform and educate audiences across our social media channels. Hear her story 👇 #AheadTogetherrT
As part of our £1bn R&D investment to get ahead of #infectiousdiseases in lower-income countries we’re working w/@DNDi @dundeeuni to discover shorter, simpler treatments for #VisceralLeishmaniasis. Learn more ⬇️ #AheadTogether twitter.com/GSK/status/154…
Nearly 900,000 people die every year from complications due to #HepatitisB. At GSK, we are using science, technology and talent to get ahead of hepatitis together. We can’t wait for a world without #hepatitis. #Hepcantwait #WorldHepatitisDay